Format

Send to

Choose Destination
Anticancer Res. 2000 Nov-Dec;20(6D):5095-8.

Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma.

Author information

1
Klinikum der Johann-Wolfgang Goethe-Universität Frankfurt, Zentrallabor-Zentrum der Inneren Medizin, Theodor-Stern-Kai 7, D-60590 Frankfurt/Main, Germany.

Abstract

Pyruvate kinase is one of the glycolytic key enzymes. It exists in various isoforms which are expressed in different cell types. One of these isoforms, the type Tu M2-PK, is strongly overexpressed by tumor cells and released into body fluids. The concentration of Tu M2-PK in body fluids can be quantitatively determined by a commercially available enzyme-linked immunosorbent assay (ELISA)-kit. The Tu M2-PK concentration was measured in EDTA-plasma of 116 patients with renal carcinoma and 42 patients suffering from nephritis, by using this kit. The ranges of the Tu M2-PK-concentrations of the two groups did not overlap, indicating a highly significant discrimination of renal carcinoma and benign renal diseases. Furthermore, the Tu M2-PK concentration in EDTA-plasma correlated strongly with the Robson tumor stage of the 116 patients. The present results indicated that the Tu M2-PK might be the first tumor marker, which could be an excellent complementation of the diagnostic program for renal carcinoma.

PMID:
11326675
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center